How Nasdaq CEO Adena Friedman Found Her Ideal Job: 'I Realized I Liked Risk-Taking More Than Risk Management'

Adobe Inc. announced that CEO Shantanu Narayen will step down after 18 years in the role. His departure comes amid investor concerns over Adobe's ability to adapt to the AI-driven market. Narayen oversaw Adobe's transformation to a subscription-based model and led the company to record revenue of $24 billion. His successor will be named in the coming months.

Unilever announced plans to adjust its CEO pay structure to attract top US leadership talent. The company emphasized that the revised compensation package is part of its strategy to remain competitive in the global market. The move reflects a broader trend among global firms to realign leadership incentives in key markets.

Harmony Biosciences reported $868.5 million in net product revenue for 2025 and reaffirmed its 2026 guidance of $1.0–$1.04 billion. CEO Jeffrey M. Dayno highlighted the company's progress in expanding the pitolisant franchise and advancing clinical trials in new indications.

Why Did Adobe's CEO Resign?

Adobe's CEO Shantanu Narayen has led the company through significant growth, including a shift to a subscription model and the expansion of AI integration in its products. However, recent investor concerns have centered on the company's ability to maintain innovation in a rapidly evolving market. Narayen's departure may signal a strategic shift to address these challenges and appoint new leadership better suited for the AI era.

Adobe's stock has declined 23% in 2026, reflecting investor uncertainty about the company's future direction. Microsoft CEO Satya Nadella praised Narayen's leadership and expressed confidence in Adobe's long-term potential.

How Do CEO Pay Adjustments Reflect Strategic Shifts?

Unilever's decision to revise its CEO pay structure aligns with a growing trend among global firms to attract and retain top talent. The company emphasized that the new incentives are tied to performance and shareholder returns. This shift reflects a broader need for global firms to adapt to market dynamics and remain competitive in leadership talent.

The move by Unilever comes as companies increasingly focus on aligning executive compensation with strategic goals. This trend is particularly relevant in markets like the United States, where executive talent is in high demand.

What to Watch for in 2026 for Harmony Biosciences

Harmony Biosciences is on track for WAKIX to reach blockbuster status in 2026. The company reported six consecutive years of revenue growth and remains on schedule for the Pitolisant GR NDA submission in Q2 2026.

Clinical trials for pitolisant in Prader-Willi syndrome and idiopathic hypersomnia are progressing, with data expected in 2026 and 2027, respectively. These developments could significantly expand the franchise's market potential.

Harmony Biosciences also highlighted legal settlements with generic filers and noted that licenses for generic WAKIX will not be available until March 2030. This timeline provides additional market exclusivity and revenue predictability.